Hinge Health (HNGE) EBITDA (2024 - 2026)

Hinge Health's EBITDA history runs 3 years deep, the most recent figure standing at $34.8 million for Q1 2026.

• In Q1 2026, EBITDA rose 103.74% year-over-year to $34.8 million; the TTM figure through Mar 2026 stood at -$524.7 million (down 3261.84% YoY), while the FY2025 annual figure was -$528.3 million, down 4330.6% from the prior year.
• EBITDA came in at $34.8 million for Q1 2026 at Hinge Health, up from $27.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $34.8 million in Q1 2026 to a low of -$580.7 million in Q2 2025.
• A 3-year average of -$63.5 million and a median of $6.6 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA sank 3208.48% in 2025 and soared 103.74% in 2026, its largest moves.
• Hinge Health's EBITDA stood at $20.9 million in 2024, then jumped by 30.35% to $27.3 million in 2025, then gained by 27.68% to $34.8 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $34.8 million, $27.3 million, and -$6.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison